F5 (FFIV)
(Delayed Data from NSDQ)
$244.29 USD
+2.27 (0.94%)
Updated Nov 21, 2024 04:00 PM ET
After-Market: $245.20 +0.91 (0.37%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
FFIV 244.29 +2.27(0.94%)
Will FFIV be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for FFIV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FFIV
GitLab Rises 13% in a Month: Buy, Sell or Hold the GTLB Stock?
Here's Why F5 Networks (FFIV) is a Strong Growth Stock
FFIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the First Trust Indxx NextG ETF (NXTG)?
NICE or FFIV: Which Is the Better Value Stock Right Now?
F5 Expands AI Portfolio: Should You Buy, Sell or Hold the Stock?
Other News for FFIV
Director Alan Higginson Sells 825 Shares of F5 Inc (FFIV)
Decoding F5 Inc (FFIV): A Strategic SWOT Insight
Alkermes, DaVita, Jabil, Ralph Lauren, among potential M&A candidates - BofA
Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
Hotchkis & Wiley Reduces Stake in PetMed Express Inc